These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25178938)

  • 1. SLC19A1 hot spot for MTX plasma concentration.
    Gutierrez-Camino A; Lopez-Lopez E; Garcia-Orad A
    Med Oncol; 2014 Oct; 31(10):204. PubMed ID: 25178938
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia.
    Wang SM; Sun LL; Zeng WX; Wu WS; Zhang GL
    Med Oncol; 2014 Jul; 31(7):62. PubMed ID: 24927955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-595 Suppresses the Cellular Uptake and Cytotoxic Effects of Methotrexate by Targeting SLC19A1 in CEM/C1 Cells.
    Wang SM; Sun LL; Wu WS; Yan D
    Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):8-13. PubMed ID: 29345051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation analysis of the SLC19A1 promoter region in Chinese children with acute lymphoblastic leukaemia.
    Wang SM; Li M; Wu WS; Sun LL; Yan D
    J Clin Pharm Ther; 2020 Aug; 45(4):646-651. PubMed ID: 32403197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
    Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
    Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can SLC19A1 80G>A polymorphisms predict risk of extremely delayed MTX excretion after high dose of methotrexate?
    Rasmussen MM; Christensen RH; Gregers J; Heldrup J; Nersting J; Schmiegelow K
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):417-8. PubMed ID: 23669721
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation between methylation level of the
    Huang X; Hao Q; Fang Q; Zhang P; Wei H; Wang Y; Wang J; Mi Y
    Pharmacogenomics; 2023 Apr; 24(5):261-268. PubMed ID: 36999405
    [No Abstract]   [Full Text] [Related]  

  • 8. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
    He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
    Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia.
    Iparraguirre L; Gutierrez-Camino A; Umerez M; Martin-Guerrero I; Astigarraga I; Navajas A; Sastre A; Garcia de Andoin N; Garcia-Orad A
    Pharmacogenet Genomics; 2016 Nov; 26(11):517-525. PubMed ID: 27649261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia.
    Faganel Kotnik B; Dolzan V; Grabnar I; Jazbec J
    Leuk Lymphoma; 2010 Apr; 51(4):724-6. PubMed ID: 20141435
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
    Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
    Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
    J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.
    Laverdière C; Chiasson S; Costea I; Moghrabi A; Krajinovic M
    Blood; 2002 Nov; 100(10):3832-4. PubMed ID: 12411325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.
    Lima A; Bernardes M; Azevedo R; Monteiro J; Sousa H; Medeiros R; Seabra V
    Toxicol Sci; 2014 Nov; 142(1):196-209. PubMed ID: 25124723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
    Lopez-Lopez E; Ballesteros J; Piñan MA; Sanchez de Toledo J; Garcia de Andoin N; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pharmacogenet Genomics; 2013 Feb; 23(2):53-61. PubMed ID: 23222202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.
    Giletti A; Vital M; Lorenzo M; Cardozo P; Borelli G; Gabus R; Martínez L; Díaz L; Assar R; Rodriguez MN; Esperón P
    Eur J Pharm Sci; 2017 Nov; 109():480-485. PubMed ID: 28887233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphism G80A in the reduced folate carrier gene and its relationship to survival and risk of relapse in acute lymphoblastic leukemia.
    Leyva-Vázquez MA; Organista-Nava J; Gómez-Gómez Y; Contreras-Quiroz A; Flores-Alfaro E; Illades-Aguiar B
    J Investig Med; 2012 Oct; 60(7):1064-7. PubMed ID: 22914600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.